Categories: Clinical TrialNews

Akari Therapeutics to Participate in the Cantor Oncology & HemOnc Conference

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

NEW YORK and LONDON, Sept. 22, 2022 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the investor-focused Cantor Oncology & HemOnc Conference on September 28, 2022. President and CEO Rachelle Jacques will take part in a conference panel, Addressing Challenges in Cell Therapy and Transplant, at 9:00 a.m. Eastern time and will attend 1:1 investor meetings.

About Akari Therapeutics

Akari Therapeutics, plc (Nasdaq: AKTX) is a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases. Akari’s lead asset, investigational nomacopan, is a bispecific recombinant inhibitor of C5 complement activation and leukotriene B4 (LTB4) activity. Akari’s pipeline includes a Phase 3 clinical trial program investigating nomacopan for severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA), as well as pre-clinical research of long-acting PAS-nomacopan in geographic atrophy (GA). For more information about Akari, please visit akaritx.com.

Investor Contact:
Mike Moyer
LifeSci Advisors
(617) 308-4306
mmoyer@lifesciadvisors.com

Media Contact:
Eliza Schleifstein
Schleifstein PR   
(917) 763-8106
eliza@schleifsteinpr.com

Staff

Recent Posts

ECOSEP and Tata Elxsi Announce Strategic Partnership to Transform Sports Medicine through AI

BENGALURU, India, May 7, 2025 /PRNewswire/ -- European College of Sport and Exercise Physicians (ECOSEP) and…

1 hour ago

Grant Industries Selects Labbit LIMS to Drive Digital Transformation Across Its Regulated Labs

Labbit's graph-based architecture supports the unique needs of Grant's different lab environments while unifying data…

1 hour ago

The Future of Ultrasound Reporting 

By Cecile Brosset, CEO of Sonio The landscape of ultrasound technology is rapidly evolving, driven…

19 hours ago

Beyond Medical Technologies Announces $2.5 Million Convertible Note Financing to Support Blockchain Attestation Platform

Vancouver, British Columbia--(Newsfile Corp. - May 6, 2025) - Beyond Medical Technologies Inc. (CSE: DOCT)…

19 hours ago

Albert Einstein College of Medicine Launches Data Science Institute

Leveraging the Power of Data to Accelerate Scientific Discovery and Improve Health in the Bronx…

19 hours ago

Plasmidsaurus Opens 10th Global Lab in Singapore, Scaling to Meet the Demand for Cutting-Edge Sequencing Around the World

SINGAPORE and SOUTH SAN FRANCISCO, Calif., May 6, 2025 /PRNewswire/ -- Plasmidsaurus, the company that…

19 hours ago